SCHEMBL693484

SCHEMBL693484

c1ccc2c(c1)[N]C1=C2CCCC1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5603961 0.73 CYP2A6 (0.33)
SCHEMBL223499 0.73 PNMT (0.38)
SCHEMBL814237 0.73
SCHEMBL1456915 0.73 PNMT (0.38)
SCHEMBL3414198 0.72 ACHE (0.33) ACHETSHR
SCHEMBL5602318 0.71 NPC1 (0.32)
SCHEMBL6754203 0.71 DRD1 (0.49) ACHETSHR
SCHEMBL29133072 0.69 TSHR (0.47) TSHR
SCHEMBL6312706 0.68 PARP1 (0.33) ACHE
SCHEMBL5603449 0.67 IDO1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114075131-A TADF material, preparation method thereof and organic electroluminescent device thereof 吉林奥来德光电材料股份有限公司 2022-02-22 CN claimed
EP-3386511-B1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2021-05-12 EP claimed
CN-107522652-B Organic light-emitting element, and light-emitting material and compound used for same 九州有机光材股份有限公司 2021-01-05 CN claimed
US-10874672-B2 Methods for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2020-12-29 US claimed
CN-110850680-A Curable composition, display element, and method for forming cured film JSR株式会社 2020-02-28 CN claimed
US-10276803-B2 Organic light-emitting device, and light-emitting material and compound used therefor KYULUX, INC. (JP) 2019-04-30 US claimed
EP-2851408-B1 ORGANIC LIGHT EMITTING DEVICE, AND LIGHT EMITTING MATERIAL AND COMPOUND USED THEREFOR KYULUX INC (JP) 2018-11-21 EP claimed
US-20170256720-A1 ORGANIC LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING MATERIAL AND COMPOUND USED THEREFOR KYULUX, INC. (JP) 2017-09-07 US claimed
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP claimed
US-9502668-B2 Organic light-emitting device, and light-emitting material and compound used therefor KYULUX, INC. (JP) 2016-11-22 US claimed
US-20060122156-A1 Heteroaryl compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-06-08 US claimed
WO-2006053109-A1 HETEROARYL COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO claimed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US claimed
WO-2005105864-A1 HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-11-10 WO claimed
EP-1117656-B1 GREY COLOURING PHOTOCHROMIC FUSED PYRANS JAMES ROBINSON LTD (GB) 2002-05-29 EP claimed
US-6387512-B1 FOR COLORING INKS, FUELS, PLASTICS OR GLASS JAMES ROBINSON LIMITED (GB) 2002-05-14 US claimed
EP-1117656-A1 GREY COLOURING PHOTOCHROMIC FUSED PYRANS JAMES ROBINSON LIMITED (GB) 2001-07-25 EP claimed
WO-2000018755-A1 GREY COLOURING PHOTOCHROMIC FUSED PYRANS JAMES ROBINSON LIMITED (GB) 2000-04-06 WO claimed
EP-0471236-B1 Imidazopyridine derivatives and their use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-03-15 EP claimed
EP-0471236-A1 Imidazopyridine derivatives and their use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-02-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10276803-B2 Organic light-emitting device, and light-emitting material and compound used therefor CRY1, WEE1, OR51E2 ACHE 1643/4885TSHR 3283/4885
US-20060122156-A1 Heteroaryl compounds IL2, CCL11, IL4 ACHE 3465/4885TSHR 3956/4885
US-20170256720-A1 ORGANIC LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING MATERIAL AND COMPOUND USED THEREFOR CRY1, WEE1, OR51E2 ACHE 1643/4885TSHR 3283/4885
US-10874672-B2 Methods for treating Huntington's disease HTT, HYPK, FH ACHE 67/4885TSHR 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.